These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 24179483)
1. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Sharma J; Duque M; Saif MW Therap Adv Gastroenterol; 2013 Nov; 6(6):474-90. PubMed ID: 24179483 [TBL] [Abstract][Full Text] [Related]
2. An update on the management of pancreatic neuroendocrine tumors. Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352 [TBL] [Abstract][Full Text] [Related]
3. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions. Bilici A Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731 [TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumors of the pancreas. Milan SA; Yeo CJ Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942 [TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045 [TBL] [Abstract][Full Text] [Related]
7. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. Ito T; Igarashi H; Jensen RT J Gastroenterol; 2012 Sep; 47(9):941-60. PubMed ID: 22886480 [TBL] [Abstract][Full Text] [Related]
8. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165 [TBL] [Abstract][Full Text] [Related]
9. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649 [TBL] [Abstract][Full Text] [Related]
10. Systemic treatment of neuroendocrine tumors with hepatic metastases. Demirkan BH; Eriksson B Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Peng L; Schwarz RE Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005 [TBL] [Abstract][Full Text] [Related]
12. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors. Krug S; Gress TM; Michl P; Rinke A Digestion; 2017; 96(2):67-75. PubMed ID: 28728148 [TBL] [Abstract][Full Text] [Related]
13. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors. Cho CM Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555 [TBL] [Abstract][Full Text] [Related]
15. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617 [TBL] [Abstract][Full Text] [Related]
16. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. Chan JA; Kulke MH Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373 [TBL] [Abstract][Full Text] [Related]
17. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Raj N; Reidy-Lagunes D Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Oberstein PE; Saif MW Clin Med Insights Oncol; 2012; 6():41-51. PubMed ID: 22253554 [TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: entering a new era. Oberstein PE; Remotti H; Saif MW; Libutti SK JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. Devata S; Kim EJ Case Rep Oncol; 2012 Sep; 5(3):622-6. PubMed ID: 23275776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]